Preclinical characterization of AB-506, an inhibitor of HBV replication targeting the viral core protein

Abstract

AB-506, a small-molecule inhibitor targeting the HBV core protein, inhibits viral replication in vitro (HepAD38 cells: EC₅₀ of 0.077 μM, CC₅₀ > 25 μM) and in vivo (HBV mouse model: ∼3.0 log₁₀ reductions in serum HBV DNA compared to the vehicle control). Binding of AB-506 to HBV core protein accelerates capsid assembly and inhibits HBV pgRNA encapsidation. Furthermore, AB-506 blocks cccDNA establishment in HBV-infected HepG2-hNTCP-C4 cells and primary human hepatocytes, leading to inhibition of viral RNA, HBsAg, and HBeAg production (EC₅₀ from 0.64 μM to 1.92 μM). AB-506 demonstrated activity across HBV genotypes A-H and maintains antiviral activity against nucleos(t)ide analog-resistant variants in vitro. Evaluation of AB-506 against a panel of core variants showed that T33N/Q substitutions results in >200-fold increase in EC₅₀ values, while L30F, L37Q, and I105T substitutions showed an 8 to 20-fold increase in EC₅₀ values in comparison to the wild-type. In vitro combinations of AB-506 with NAs or an RNAi agent were additive to moderately synergistic. AB-506 exhibits good oral bioavailability, systemic exposure, and higher liver to plasma ratios in rodents, a pharmacokinetic profile supporting clinical development for chronic hepatitis B.

Keywords: AB-506; Aminoindane; CHB; Capsid inhibitor; HBV; pgRNA encapsidation.